SCHEMBL1267145

SCHEMBL1267145

O=C(c1ccc2c(c1)OCO2)N1CCn2cccc2C1c1cccs1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 7/20 0.43
HPGD P15428 5/20 0.43
NPC1 O15118 4/20 0.43
RAB9A P51151 3/20 0.43
CTNNB1 P35222 1/20 0.43
WNT3A P56704 1/20 0.43
HSD17B10 Q99714 2/20 0.42
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
SMN1; SMN2 Q16637 3/20 0.42
TP53 P04637 2/20 0.42
MAPT P10636 2/20 0.41
TSHR P16473 3/20 0.41
LMNA P02545 2/20 0.41
USP2 O75604 1/20 0.41
MAPK1 P28482 1/20 0.41
GFER P55789 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1267130 0.82 ALDH1A1 (0.49) ALDH1A1NPC1SMN1; SMN2MAPTTSHR
SCHEMBL1267179 0.82 ALDH1A1 (0.46) ALDH1A1HPGDNPC1RAB9AHSD17B10
SCHEMBL1266653 0.81 ALDH1A1 (0.46) ALDH1A1CYP3A4CYP2C9CYP2C19SMN1; SMN2
SCHEMBL1266315 0.81 ABL1 (0.46) ALDH1A1HPGDSMN1; SMN2MAPTKDM4E
SCHEMBL1266359 0.80 ALDH1A1 (0.50) ALDH1A1HPGDNPC1RAB9ACTNNB1
SCHEMBL1267175 0.80 ALDH1A1 (0.44) ALDH1A1HPGDNPC1RAB9ACTNNB1
SCHEMBL1267045 0.79 KIF11 (0.48) ALDH1A1HPGDNPC1RAB9AHSD17B10
SCHEMBL1266012 0.79 ADRA2C (0.55) ALDH1A1HPGDNPC1RAB9AHSD17B10
SCHEMBL1267022 0.79 NPC1 (0.47) ALDH1A1HPGDNPC1RAB9AHSD17B10
SCHEMBL1266971 0.78 NPC1 (0.46) ALDH1A1HPGDNPC1RAB9ACTNNB1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7879858-B2 monoamine reuptake inhibitors such as (3-fluorophenyl)(1-(2-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone, used as antidepressants, anxiolytic agents and analgesics GRUENENTHAL GMBH (DE) 2011-02-01 US claimed
US-20090258880-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions GRUENENTHAL GMBH (DE) 2009-10-15 US claimed
US-7879858-B2 monoamine reuptake inhibitors such as (3-fluorophenyl)(1-(2-methoxyphenyl)-3,4-dihydropyrrolo[1,2-a]pyrazin-2(1H)-yl)methanone, used as antidepressants, anxiolytic agents and analgesics GRUENENTHAL GMBH (DE) 2011-02-01 US disclosed
US-20090258880-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions GRUENENTHAL GMBH (DE) 2009-10-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090258880-A1 Substituted Tetrahydropyrrolopyrazine Compounds and the Use Thereof in Pharmaceutical Compositions DHPS, APC, CYP3A5 ALDH1A1 559/4885HPGD 61/4885NPC1 2158/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.